| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.10 | -0.01 (-0.24%) | 2.65 - 5.36 | 3.0 million (Below Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 4.15 |
|---|---|
| Previous Close | 4.11 |
| Day's Range | 3.97 - 4.25 |
| Market Cap | 472.1M |
| Avg Volume (10 Day) | 3.5M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.07 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
PR Newswire - Thursday 05/09/2013 4:10 PM ET
Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
PR Newswire - Wednesday 05/08/2013 7:00 AM ET
Sequenom, Inc. Announces Date of First Quarter 2013 Financial Results and Conference Call
PR Newswire - Thursday 04/25/2013 7:00 AM ET
| SQNM | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 97.63% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 6.14 | |
| LT Debt/Equity | 5.80 | |
| Earnings Yield | -- | |
| Price/Sales | 4.17 |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 6.75 | -8.66% |
| Protalix Biotherapeutics Inc | 5.16 | -1.15% |
| Spectrum Pharmaceuticals Inc | 8.14 | +0.74% |
| Sangamo BioSciences Inc | 8.43 | +2.06% |
| Hyperion Therapeutics Inc | 22.33 | 0.00% |
Data is delayed by at least 15 min.